Doceree has launched Semmelweis, an AI model specifically designed for pharmaceutical commercialization, as drugmakers increase their AI investments in marketing and sales operations. The model is built to identify prescribing signals early while adhering to industry compliance requirements.
TL;DR
- Doceree introduces Semmelweis, an AI model tailored for pharma commercialization, leveraging clinical intent signals.
- The model is designed to operate within medical, legal, and regulatory guidelines, setting it apart from general-purpose AI models.
- Semmelweis underpins Doceree's Daily Command and other products, aiming to optimize prescription fills and refills.
What happened
Doceree has unveiled Semmelweis, an AI model built for pharmaceutical commercialization. The model is part of Doceree's Daily Command commercial operating system and other products. Semmelweis is designed to identify prescribing signals early while complying with industry regulations.
The model draws on clinical context rather than the open web, utilizing treatment pathways, care behavior, and prescribing intent through Clinical Intent Signals (CIS). It is built on frontier AI systems for language and reasoning, with proprietary components that general-purpose models cannot replicate.
Semmelweis operates within a bounded action space, working only with de-identified, HCP-level context and recommending actions that comply with medical, legal, and regulatory guidelines. The model also features a closed measurement loop, where observed outcomes feed back into future recommendations to improve precision over time.
Why it matters
The launch of Semmelweis comes as large pharmaceutical companies increase their AI investments in commercial operations, not just in research and development. This shift highlights the growing importance of AI in marketing and sales within the pharma industry.
Doceree's model is designed to operate invisibly to clients, providing recommendations that are grounded in clinical context, human-approved, and ready for medical, legal, and regulatory review. This approach sets it apart from general-purpose AI models that may not comply with industry regulations.
The model's focus on optimizing filled and refilled prescriptions rather than impressions or claims aligns with the pharma industry's need for precise and compliant marketing tools. This could make Semmelweis a valuable asset for pharmaceutical companies looking to enhance their commercial operations.
Key facts
- Semmelweis is built on frontier AI systems for language and reasoning, with proprietary components that general-purpose models cannot replicate.
- The model draws on Doceree's ESPYIAN identity graph of over 6 million verified healthcare providers and 185 direct electronic health record integrations.
- Semmelweis operates within a bounded action space, working only with de-identified, HCP-level context and recommending actions that comply with medical, legal, and regulatory guidelines.
- The model features a closed measurement loop, where observed outcomes feed back into future recommendations to improve precision over time.
- Semmelweis underpins Doceree's Daily Command commercial operating system and other products, including the Clinical Intent Suite, RepTwin field-agent tool, Co-pay.com, and the Doceree Marketplace.
- The model is designed to optimize filled and refilled prescriptions rather than impressions or claims.
- Doceree said the model is meant to operate invisibly to clients, providing recommendations that are grounded in clinical context, human-approved, and ready for medical, legal, and regulatory review.
- Pfizer plans to add more than 1,200 graphics processing units over the next two years to support an AI buildout, highlighting the industry's increasing investment in AI for commercial operations.
Context
The pharmaceutical industry is increasingly turning to AI to enhance marketing and sales operations, moving beyond traditional research and development applications. This shift is driven by the need for more precise and compliant marketing tools that can navigate the complex regulatory landscape of the pharma industry.
Doceree's Semmelweis model represents a significant step in this direction, offering a tailored solution that addresses the specific needs of pharmaceutical commercialization. Its focus on clinical intent signals and compliance sets it apart from general-purpose AI models, making it a valuable tool for pharma companies.
As the industry continues to invest in AI, models like Semmelweis could become increasingly important in optimizing marketing and sales operations, ultimately leading to more effective and compliant commercial strategies.
